Treatment with buprenorphine linked to reduced opioid use: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-06-12 04:15 GMT   |   Update On 2021-06-12 06:47 GMT
Advertisement

USA: Treatment with buprenorphine-naloxone versus methadone results in a greater reduction of opioid use among adults with mental disorders and comorbid opioid use disorder (OUD), finds a recent study in the journal Addiction.

In patients with OUD, mental disorders are common, the researchers noted a need to incorporate complex factors involved in influencing outcomes of medication treatment for OUD (MOUD).

Advertisement

Against the above background, Yih-Ing Hser, University of California, Los Angeles, and colleagues aimed to investigate whether a reduction in opioid use differs when treated by either buprenorphine-naloxone (BUP) or methadone (MET) among adults with comorbid OUD and mental disorders.

Adults with OUD were randomized to receive either BUP or MET treatment for 24 weeks and followed up in three yearly assessments. The present secondary analyses were based on 597 participants who completed all assessments.

The outcome measures were the number of days of using opioids per month during the follow-up period. The Mini-International Neuropsychiatric Interview (MINI) was used to classify participants into three groups: Lifetime Mood Disorder (n=302), Lifetime Mental Disorder Other Than Mood Disorder (n=114), and No Mental Disorder (n=181).

A time-varying predictor was medication treatment (BUP, MET, no treatment) during the follow-up period. 

Key findings of the study include:

  • Based on Zero-Inflated Poisson (ZIP) mixed regression analysis, it was found that relative to no treatment, opioid use during the follow-up was significantly reduced by BUP (OR, 0.12 for any use; RR, 0.77 for days of use) and by MET (OR, 0.33 for any use; RR, 0.78 for days of use).
  • Relative to MET, BUP was associated with a lower likelihood of any opioid use among participants with mood disorders (OR, 0.52) and for participants without mental disorder (OR, 0.37), and fewer number of days using opioids (RR, 0.37) among participants with other mental disorders.

Reference:

The study titled, "Long-term Follow-up Assessment of Opioid Use Outcomes among Individuals with Comorbid Mental Disorders and Opioid Use Disorder Treated with Buprenorphine or Methadone in a Randomized Clinical Trial," is published in the journal Addiction. 

DOI: https://onlinelibrary.wiley.com/doi/10.1111/add.15594

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News